Art Rastinehad, DO, has been recognized as a 2026 Castle Connolly Top Doctor, marking the 12th year he has received this prestigious designation. Only 7 percent of the nation's licensed physicians are selected annually as Castle Connolly Top Doctors for their specialties in their regions. This recognition underscores Dr. Rastinehad's significant contributions to urology and radiology, particularly in the field of precision prostate cancer care.
Dr. Rastinehad serves as professor of urology and radiology, vice chair of urology at Northwell's Lenox Hill Hospital, and Northwell Health System director for prostate cancer. His clinical and research work focuses on precision prostate cancer diagnosis, MRI-targeted biopsy, focal therapy, image-guided treatment, interventional urology, and prostate artery embolization for enlarged prostate/BPH. His unique background as the first dual fellowship-trained urologic oncologist and interventional radiologist allows him to combine cancer surgery, advanced imaging, and minimally invasive image-guided therapy in one clinical practice.
“Being recognized as a Castle Connolly Top Doctor is meaningful because it reflects the trust patients and peers place in our work,” said Dr. Rastinehad. “My goal is to help men make clear, informed decisions about prostate cancer, enlarged prostate, and urinary symptoms by coordinating the right evaluation and the most appropriate treatment options for each individual patient.”
Dr. Rastinehad's research team has helped shape the field of image-guided prostate care, including early validation of MR/US fusion biopsy for prostate cancer detection in the United States. His work continues to advance prostate cancer diagnosis, focal therapy planning, minimally invasive treatment, and interventional options for men with BPH. Key achievements include being part of the first team to publish a series on prostate artery embolization in 2006, early validation of MR/US fusion biopsy, and serving as principal investigator in the development and clinical use of UroNav/Philips MR/US fusion technology for prostate biopsy and focal therapy planning. He is also a founding executive board member of the Focal Therapy Society.
With more than 20 years of experience in prostate artery embolization and interventional urology, Dr. Rastinehad continues to develop advanced image-guided planning and annotation tools for focal therapy. His practice at the urology department at Lenox Hill Hospital provides advanced prostate care for men with elevated PSA, abnormal prostate MRI, localized prostate cancer, enlarged prostate/BPH, urinary symptoms, and complex prostate treatment decisions.
The Castle Connolly Top Doctor selection process is physician-led and based on peer nominations. Doctors do not and cannot pay to be selected. This honor highlights Dr. Rastinehad's commitment to precision prostate care, which emphasizes matching the right patient to the right diagnosis and treatment rather than a one-size-fits-all approach. As prostate cancer remains a significant health concern for men, Dr. Rastinehad's work has implications for improving patient outcomes through personalized, image-guided therapies. His continued recognition by Castle Connolly reinforces the importance of advancing minimally invasive and targeted treatments in urology.
